Skip to content

Pancreatic Insulin Production Capacity (PIPC) - a Feasibility Study

The Feasibility of an Innovative Protocol to Demonstrate the Impact of Positive Energy Balance on Pancreatic Insulin Production Capacity (PIPC)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06462170
Acronym
PIPC
Enrollment
90
Registered
2024-06-17
Start date
2024-06-24
Completion date
2026-12-31
Last updated
2026-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Brief summary

The standard treatment for Type 2 diabetes involves management of the disease based on average of blood glucose control over the past few months. In this study, the investigators test for the participants' ability to produce insulin, which is the hormone that the body makes to control blood sugar levels. The body produces insulin in response to eating. The participants will drink a meal replacement shake, and then test the blood for levels of insulin produced over 2 hours. With blood tests taken five times over two hours, the investigators will measure the blood glucose (sugar), and insulin levels. This study will assess the differences in insulin produced in the participants and try to understand the reasons for these differences.

Detailed description

This study will measure the ability of the pancreas to produce insulin after the participant drinks a Boost Original meal replacement shake. The Boost Original meal replacement shake contains nutrients similar to a typical meal, and allows to standardize this "meal" for all participants. This is a cross-sectional study for 90 participants with type 2 diabetes mellitus who undergo a single study visit that lasts 2 hours with blood drawn at five time points. The area under the curve will be a quantitative measure of each participant's pancreatic insulin production capacity.

Interventions

DIETARY_SUPPLEMENTBoost Original meal replacement shake

One bottle of Boost Original meal replacement shake.

Sponsors

Ottawa Hospital Research Institute
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Consent provided 2. Age \>= 18 years. 3. Diagnosed as type 2 diabetes mellitus. 4. Not on insulin therapy.

Exclusion criteria

1. Diagnosed as another form of diabetes mellitus. 2. Allergic to one or more ingredients in Boost meal replacement shake. 3. Unable to fast since midnight and attend in person for the morning protocol.

Design outcomes

Primary

MeasureTime frameDescription
Pancreatic insulin production capacity (PIPC) represented by the participant's insulin and C-peptide levels after drinking the meal replacement shake.12 monthsParticipants will get blood drawn at time 0, 30, 60, 90, and 120 minutes. Blood will be sent for glucose, insulin, and C-peptide measurements. The area under the curve (AUC) will be calculated from these measurements. The AUC for insulin and for C-peptide will be representative of the participant's PIPC.

Secondary

MeasureTime frameDescription
The impact of participant's self-reported weight gain in the past year (12 months prior to the single study visit) on participant's PIPC.12 monthsLinear regression modelling will be used where weight gain is an independent variable, and PIPC is the dependent variable. The p-value for participant's self-reported weight gain will show the significance of impact on PIPC.

Countries

Canada

Contacts

CONTACTCathy Sun, MD MSc
csun@toh.ca613-738-8333
PRINCIPAL_INVESTIGATORCathy Sun, MD MSc

Ottawa Hospital Research Institute

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 7, 2026